Header Logo

SEYED JALALI

TitleAssistant Professor
InstitutionBaylor College of Medicine
DepartmentDepartment of Neurology
Address2401 S 31st Street
Temple, TX 25472
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Shekari N, Shanehbandi D, Baghbani E, Safaei S, Masoumi J, Baradaran B, Jalali SA. Correction: VSIG-3/IGSF11 silencing in A2058 melanoma cells simultaneously suppresses melanoma progression and induces anti-tumoral cytokine profile in human T cells: In silico and in vitro study. Naunyn Schmiedebergs Arch Pharmacol. 2025 Oct; 398(10):14545-14546. PMID: 40817919.
      Citations:    Fields:    
    2. Shekari N, Shanehbandi D, Baghbani E, Safaei S, Masoumi J, Baradaran B, Jalali SA. VSIG-3/IGSF11 silencing in A2058 melanoma cells simultaneously suppresses melanoma progression and induces anti-tumoral cytokine profile in human T cells: In silico and in vitro study. Naunyn Schmiedebergs Arch Pharmacol. 2025 Apr; 398(4):3861-3880. PMID: 39365310.
      Citations:    
    3. Ramezani-Aliakbari K, Jalali SA, Alinejad M, Jeddi-Tehrani M, Shabani M. 5-Fluorouracil Effectively Depletes Tumor Induced Myeloid Derived Suppressor Cells in 4T1 Mammary Carcinoma Model. Avicenna J Med Biotechnol. 2024 Oct-Dec; 16(4):244-250. PMID: 39606677; PMCID: PMC11589428.
      Citations:    
    4. Chamani FK, Etebari A, Hajivalili M, Mosaffa N, Jalali SA. Hypoxia and programmed cell death-ligand 1 expression in the tumor microenvironment: a review of the effects of hypoxia-induced factor-1 on immunotherapy. Mol Biol Rep. 2024 Jan 06; 51(1):88. PMID: 38183512.
      Citations:    
    5. Shekari N, Shanehbandi D, Kazemi T, Zarredar H, Baradaran B, Jalali SA. VISTA and its ligands: the next generation of promising therapeutic targets in immunotherapy. Cancer Cell Int. 2023 Nov 07; 23(1):265. PMID: 37936192; PMCID: PMC10631023.
      Citations:    
    6. Alimohammadi M, Ghaffari-Nazari H, Alimohammadi R, Bakhshandeh M, Jalali SA, Rezaei N. Radiotherapy Combination: Insight from Tumor Immune Microenvironment (TIME). Avicenna J Med Biotechnol. 2023 Oct-Dec; 15(4):209-215. PMID: 38078341; PMCID: PMC10709758.
      Citations:    
    7. Najafi A, Keykhaee M, Kazemi MH, Karimi MY, Khorramdelazad H, Aghamohamadi N, Bolouri MR, Ghaffari-Nazari H, Mirsharif ES, Karimi M, Dehghan Manshadi HR, Mahdavi SR, Safari E, Jalali SA, Falak R, Khoobi M. Catalase-gold nanoaggregates manipulate the tumor microenvironment and enhance the effect of low-dose radiation therapy by reducing hypoxia. Biomed Pharmacother. 2023 Nov; 167:115557. PMID: 37757491.
      Citations:    
    8. Khani Chamani F, Shabani M, Moradi A, Alinejad M, Jalali SA. Evaluation of Molecular-level Changes of Programmed Cell Death Ligand-1 after Radiation Therapy in a BALB/c CT26 Colorectal Mouse Tumor Model. Iran J Allergy Asthma Immunol. 2023 Apr 30; 22(2):163-171. PMID: 37496409.
      Citations:    
    9. Alimohammadi R, Mahmoodi Chalbatani G, Alimohammadi M, Ghaffari-Nazari H, Rahimi A, Mortaz E, Mossafa N, Boon L, Jalali SA. Dual blockage of both PD-L1 and CD47 enhances the therapeutic effect of oxaliplatin and FOLFOX in CT-26 mice tumor model. Sci Rep. 2023 02 11; 13(1):2472. PMID: 36774400; PMCID: PMC9922272.
      Citations:    
    10. Rostami E, Bakhshandeh M, Ghaffari-Nazari H, Alinezhad M, Alimohammadi M, Alimohammadi R, Mahmoodi Chalbatani G, Hejazi E, Webster TJ, Tavakkol-Afshari J, Jalali SA. Combining ablative radiotherapy and anti CD47 monoclonal antibody improves infiltration of immune cells in tumor microenvironments. PLoS One. 2022; 17(8):e0273547. PMID: 36018888; PMCID: PMC9417014.
      Citations:    
    11. Chalbatani GM, Momeni SA, Mohammadi Hadloo MH, Karimi Z, Hadizadeh M, Jalali SA, Miri SR, Memari F, Hamblin MR. Comprehensive analysis of ceRNA networks to determine genes related to prognosis, overall survival, and immune infiltration in clear cell renal carcinoma. Comput Biol Med. 2022 02; 141:105043. PMID: 34839901.
      Citations:    
    12. Mehdinejadiani K, Hashemi A, Bandehpour M, Rahmani H, Ranjbar MM, Yardel V, Jalali SA, Mosaffa N. Evaluationof the New Outer Membrane Protein A Epitope-based Vaccines for Mice Model of Acinetobacter baumannii Associated Pneumonia and Sepsis Infection. Iran J Allergy Asthma Immunol. 2021 Sep 28; 20(5):537-549. PMID: 34664813.
      Citations:    
    13. Biari N, Alavizadeh SH, Chavoshian O, Abbasi A, Saberi Z, Jalali SA, Khamesipoure A, Jaafari MR, Badiee A. Sphingomyelin liposome bearing whole Leishmania lysate antigens induce strong Th2 immune response in BALB/c mice. Iran J Basic Med Sci. 2021 Feb; 24(2):222-231. PMID: 33953862; PMCID: PMC8061322.
      Citations:    
    14. Masoumi E, Mirzaei A, Ghaffari-Nazari H, Tahaghoghi-Hajghorbani S, Jalali SA, Tavakkol-Afshari J. Serum Levels of Soluble Fas and Fas Ligand in Iranian Women with Pre-eclampsia. Rep Biochem Mol Biol. 2021 Jan; 9(4):394-398. PMID: 33969132; PMCID: PMC8068453.
      Citations:    
    15. Naghibi L, Yazdani M, Momtazi-Borojeni AA, Razazan A, Shariat S, Mansourian M, Arab A, Barati N, Arabsalmani M, Abbasi A, Saberi Z, Badiee A, Jalali SA, Jaafari MR. Preparation of nanoliposomes containing HER2/neu (P5+435) peptide and evaluation of their immune responses and anti-tumoral effects as a prophylactic vaccine against breast cancer. PLoS One. 2020; 15(12):e0243550. PMID: 33301467; PMCID: PMC7728212.
      Citations:    
    16. Dana H, Chalbatani GM, Jalali SA, Mirzaei HR, Grupp SA, Suarez ER, Rap?so C, Webster TJ. CAR-T cells: Early successes in blood cancer and challenges in solid tumors. Acta Pharm Sin B. 2021 May; 11(5):1129-1147. PMID: 34094824; PMCID: PMC8144892.
      Citations:    
    17. Alimohammadi R, Alibeigi R, Nikpoor AR, Chalbatani GM, Webster TJ, Jaafari MR, Jalali SA. Encapsulated Checkpoint Blocker Before Chemotherapy: The Optimal Sequence of Anti-CTLA-4 and Doxil Combination Therapy. Int J Nanomedicine. 2020; 15:5279-5288. PMID: 32801691; PMCID: PMC7394514.
      Citations:    
    18. Zinatizadeh MR, Schock B, Chalbatani GM, Zarandi PK, Jalali SA, Miri SR. The Nuclear Factor Kappa B (NF-kB) signaling in cancer development and immune diseases. Genes Dis. 2021 May; 8(3):287-297. PMID: 33997176; PMCID: PMC8093649.
      Citations:    
    19. Alinezhad M, Bakhshandeh M, Rostami E, Alimohamadi R, Mosaffa N, Jalali SA. Synergistic effects of anti-PDL-1 with ablative radiation comparing to other regimens with same biological effect dose based on different immunogenic response. PLoS One. 2020; 15(4):e0231507. PMID: 32287292; PMCID: PMC7156084.
      Citations:    
    20. Tran AM, Chalbatani GM, Berland L, Cruz De Los Santos M, Raj P, Jalali SA, Gharagouzloo E, Ivan C, Dragomir MP, Calin GA. A New World of Biomarkers and Therapeutics for Female Reproductive System and Breast Cancers: Circular RNAs. Front Cell Dev Biol. 2020; 8:50. PMID: 32211400; PMCID: PMC7075436.
      Citations: 20     
    21. Farzad N, Barati N, Momtazi-Borojeni AA, Yazdani M, Arab A, Razazan A, Shariat S, Mansourian M, Abbasi A, Saberi Z, Badiee A, Jalali SA, Jaafari MR. P435 HER2/neu-derived peptide conjugated to liposomes containing DOPE as an effective prophylactic vaccine formulation for breast cancer. Artif Cells Nanomed Biotechnol. 2019 Dec; 47(1):665-673. PMID: 30829072.
      Citations:    
    22. Mehdinejadiani K, Bandehpour M, Hashemi A, Ranjbar MM, Taheri S, Jalali SA, Mosaffa N. In Silico Design and Evaluation of Acinetobacter baumannii Outer Membrane Protein a Antigenic Peptides As Vaccine Candidate in Immunized Mice. Iran J Allergy Asthma Immunol. 2019 Nov 10; 18(6):655-663. PMID: 32245309.
      Citations:    
    23. Jalali SAH, Mohammadinezhad R, Mohammadi A, Latifian MH, Talebi M, Soleimanin-Zad S, Golkar P, Hemmatzadeh F. Molecular evolution and selection pressure analysis of infectious hematopoietic necrosis virus (IHNV) revealed the origin and phylogenetic relationship of Iranian isolates in recent epidemics in Iran. Virology. 2019 09; 535:45-58. PMID: 31272011.
      Citations:    
    24. Golchin S, Alimohammadi R, Rostami Nejad M, Jalali SA. Synergistic antitumor effect of anti-PD-L1 combined with oxaliplatin on a mouse tumor model. J Cell Physiol. 2019 11; 234(11):19866-19874. PMID: 30941773.
      Citations:    
    25. Rastakhiz S, Yazdani M, Shariat S, Arab A, Momtazi-Borojeni AA, Barati N, Mansourian M, Amin M, Abbasi A, Saberi Z, Jalali SA, Badiee A, Jaafari MR. Preparation of nanoliposomes linked to HER2/neu-derived (P5) peptide containing MPL adjuvant as vaccine against breast cancer. J Cell Biochem. 2019 Feb; 120(2):1294-1303. PMID: 30378147.
      Citations:    
    26. Jalali SA, Homaei Shandiz F, Tavakol Afshari J, Davarpanah Tanha Ghochan M, Nikpoor AR, Mohammadi M. Status of FAS and FAS Ligand Gene Polymorphisms in Patients with Breast Cancer in Northeastern IRAN. Rep Biochem Mol Biol. 2018 Oct; 7(1):23-29. PMID: 30324114; PMCID: PMC6175584.
      Citations:    
    27. Kharazian B, Lohse SE, Ghasemi F, Raoufi M, Saei AA, Hashemi F, Farvadi F, Alimohamadi R, Jalali SA, Shokrgozar MA, Hadipour NL, Ejtehadi MR, Mahmoudi M. Bare surface of gold nanoparticle induces inflammation through unfolding of plasma fibrinogen. Sci Rep. 2018 08 22; 8(1):12557. PMID: 30135553; PMCID: PMC6105630.
      Citations:    
    28. Ghasemi Z, Varasteh AR, Moghadam M, Jalali SA, Anissian A, Sankian M. Sublingual Immunotherapy with Sal k1 Expressing Lactococcus lactis Down-regulates Th2 Immune Responses in Balb/c Mice. Iran J Allergy Asthma Immunol. 2018 Jun; 17(3):281-290. PMID: 29908546.
      Citations:    
    29. Saremi SS, Shahryari M, Ghoorchian R, Eshaghian H, Jalali SA, Nikpoor AR, Jafari MR, Badiee A. The role of nanoliposome bilayer composition containing soluble leishmania antigen on maturation and activation of dendritic cells. Iran J Basic Med Sci. 2018 May; 21(5):536-545. PMID: 29922436; PMCID: PMC6000213.
      Citations:    
    30. Gholizadeh Z, Tavakkol-Afshari J, Nikpoor AR, Jalali SA, Jaafari MR. Enhanced immune response induced by P5 HER2/neu-derived peptide-pulsed dendritic cells as a preventive cancer vaccine. J Cell Mol Med. 2018 01; 22(1):558-567. PMID: 28944998; PMCID: PMC5742681.
      Citations:    
    31. Nikpoor AR, Tavakkol-Afshari J, Sadri K, Jalali SA, Jaafari MR. Improved tumor accumulation and therapeutic efficacy of CTLA-4-blocking antibody using liposome-encapsulated antibody: In vitro and in vivo studies. Nanomedicine. 2017 Nov; 13(8):2671-2682. PMID: 28847682.
      Citations:    
    32. Tahaghoghi-Hajghorbani S, Tavakkol-Afshari J, Jaafari MR, Ghaffari-Nazari H, Masoumi E, Jalali SA. Improved Immunogenicity Against a Her2/neu-Derived Peptide by Employment of a Pan HLA DR-Binding Epitope and CpG in a BALB/c Mice Model. Anticancer Agents Med Chem. 2017; 17(6):851-858. PMID: 27924731.
      Citations:    
    33. Yazdani M, Jalali SA, Badiee A, Shariat S, Mansourian M, Arabi L, Abbasi A, Saberi Z, Jaafari MR. Stimulation of Tumor-Specific Immunity by p5 HER-2/neu Generated Peptide Encapsulated in Nano-liposomes with High Phase Transition Temperature Phospholipids. Curr Drug Deliv. 2017; 14(4):492-502. PMID: 27411392.
      Citations:    
    34. Safavi-Sohi R, Maghari S, Raoufi M, Jalali SA, Hajipour MJ, Ghassempour A, Mahmoudi M. Bypassing Protein Corona Issue on Active Targeting: Zwitterionic Coatings Dictate Specific Interactions of Targeting Moieties and Cell Receptors. ACS Appl Mater Interfaces. 2016 Sep 07; 8(35):22808-18. PMID: 27526263.
      Citations:    
    35. Masoumi E, Tavakkol-Afshari J, Nikpoor AR, Ghaffari-Nazari H, Tahaghoghi-Hajghorbani S, Jalali SA. Relationship between Fas and Fas Ligand gene polymorphisms and pre-eclampsia. J Obstet Gynaecol Res. 2016 Oct; 42(10):1272-1278. PMID: 27277758.
      Citations:    
    36. Alipour Talesh G, Ebrahimi Z, Badiee A, Mansourian M, Attar H, Arabi L, Jalali SA, Jaafari MR. Poly (I:C)-DOTAP cationic nanoliposome containing multi-epitope HER2-derived peptide promotes vaccine-elicited anti-tumor immunity in a murine model. Immunol Lett. 2016 08; 176:57-64. PMID: 27260485.
      Citations:    
    37. Fakhraee F, Badiee A, Alavizadeh SH, Jalali SA, Chavoshian O, Khamesipour A, Mahboudi F, Jaafari MR. Coadminstration of L. major amastigote class I nuclease (rLmaCIN) with LPD nanoparticles delays the progression of skin lesion and the L. major dissemination to the spleen in BALB/c mice-based experimental setting. Acta Trop. 2016 Jul; 159:211-8. PMID: 27060774.
      Citations:    
    38. Mehravaran A, Jaafari MR, Jalali SA, Khamesipour A, Ranjbar R, Hojatizade M, Badiee A. The role of ISCOMATRIX bilayer composition to induce a cell mediated immunity and protection against leishmaniasis in BALB/c mice. Iran J Basic Med Sci. 2016 Feb; 19(2):178-86. PMID: 27081463; PMCID: PMC4818366.
      Citations:    
    39. Ghaffari-Nazari H, Tavakkol-Afshari J, Jaafari MR, Tahaghoghi-Hajghorbani S, Masoumi E, Jalali SA. Improving Multi-Epitope Long Peptide Vaccine Potency by Using a Strategy that Enhances CD4+ T Help in BALB/c Mice. PLoS One. 2015; 10(11):e0142563. PMID: 26556756; PMCID: PMC4640540.
      Citations:    
    40. Nikpoor AR, Tavakkol-Afshari J, Gholizadeh Z, Sadri K, Babaei MH, Chamani J, Badiee A, Jalali SA, Jaafari MR. Nanoliposome-mediated targeting of antibodies to tumors: IVIG antibodies as a model. Int J Pharm. 2015 Nov 10; 495(1):162-170. PMID: 26302860.
      Citations:    
    41. Shariat S, Badiee A, Jalali SA, Mansourian M, Yazdani M, Mortazavi SA, Jaafari MR. P5 HER2/neu-derived peptide conjugated to liposomes containing MPL adjuvant as an effective prophylactic vaccine formulation for breast cancer. Cancer Lett. 2014 Dec 01; 355(1):54-60. PMID: 25224570.
      Citations:    
    42. Mansourian M, Badiee A, Jalali SA, Shariat S, Yazdani M, Amin M, Jaafari MR. Effective induction of anti-tumor immunity using p5 HER-2/neu derived peptide encapsulated in fusogenic DOTAP cationic liposomes co-administrated with CpG-ODN. Immunol Lett. 2014 Nov; 162(1 Pt A):87-93. PMID: 25086399.
      Citations:    
    JALALI's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (169)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _